EP Patent

EP2966175A1 — Pharmaceutical compositions containing cortexolone-17-alpha-propionate

Assigned to Cassiopea SpA · Expires 2016-01-13 · 10y expired

What this patent protects

The present invention refers to pharmaceutical compositions containing new crystalline forms of cortexolone 17α-propionate. These compositions are useful for the treatment of pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendag…

USPTO Abstract

The present invention refers to pharmaceutical compositions containing new crystalline forms of cortexolone 17α-propionate. These compositions are useful for the treatment of pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages.

Drugs covered by this patent

Patent Metadata

Patent number
EP2966175A1
Jurisdiction
EP
Classification
—
Expires
2016-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Cassiopea SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.